TScan Therapeutics Shares Are Trading Lower After the Company Announced That It Commenced a $125 Million Proposed Public Offering. The Company Provided an Update on Its Solid Tumor and Heme Malignancies Clinical Programs
TScan Therapeutics宣布开始进行1.25亿美元的拟议公开募股后，该公司股价走低。该公司提供了其实体瘤和血红素恶性肿瘤临床项目的最新情况